News
PRPO
--
0.00%
--
Seth Klarman's Translate Bio Stake Dissolved Upon Acquisition
GuruFocus News · 09/17 17:19
Seth Klarman Dissolves Translate Bio Stake Upon Acquisition
GuruFocus News · 09/17 17:19
Seth Klarman's 5 Most Profitable Holdings
GuruFocus News · 09/16 19:32
Translate Bio Inc (TBIO) CEO Ronald C Jr Renaud Sold $36.3 million of Shares
GuruFocus News · 09/15 12:15
Is Precipio a Good Diagnostics & Research Stock to Invest In?
StockNews.com · 09/01 08:40
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 08/30 13:01
28 Stocks Moving in Monday's Pre-Market Session
Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) rose 86.1% to $9.87 in pre-market trading after jumping over 80% on Friday. The company recently reported a Q2 loss of $5.13 per share.
Benzinga · 08/30 11:05
60 Biggest Movers From Yesterday
Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 80.9% to close at $5.30 on Friday. The company recently reported a Q2 loss of $5.13 per share.
Benzinga · 08/30 09:18
NeuroMetrix, Reneo Pharmaceuticals leads healthcare gainers; Cassava Sciences, Applied Therapeutics among major losers
Gainers: NeuroMetrix (NASDAQ:NURO) +54%, Reneo Pharmaceuticals (NASDAQ:RPHM) +24%, Neoleukin Therapeutics (NASDAQ:NLTX) +21%, Chembio Diagnostics (NASDAQ:CEMI) +17%, InspireMD (NASDAQ:NSPR) +14%. Losers: Cassava Sciences (NASDAQ:SAVA) -28%, Applied Therape...
Seekingalpha · 08/27 15:06
Precipio Reports Partnership With American Oncology Network To Adopt Co.'s HemeScreen Technology, No Terms Disclosed
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), and American Oncology Network, LLC (AON), a high-growth community oncology provider, announces the signing of an agreement under which AON will
Benzinga · 08/26 14:01
American Oncology Network Partners with Precipio to Bring HemeScreen® into AON’s Laboratory
HemeScreen Assays will enable AON to deliver rapid patient diagnostics for hematologic malignancies through advanced molecular screening technologyNEW HAVEN, Conn. and FORT MYERS, Fla., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company...
GlobeNewswire · 08/26 14:00
Precipio Gets Multi-Year Deal for HemeScreen From American Oncology Network Physicians Group
MT Newswires · 08/26 11:36
Notable earnings after Thursday's close
BILL, DELL, DOMO, GPS, HPQ, LTRX, MRVL, OLLI, OTCQX:PLNHF, PRPO, PTON, RCEL, VMW, WDAY For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 08/25 21:35
Precipio Reschedules Q2-2021 Shareholder Update Call
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be rescheduling its Q2-2021 update call from Monday August 23 to Thursday, August 26 at 5:00 PM ET due to a schedule conflict.
GlobeNewswire · 08/20 21:00
Precipio Corrects Announcement of Q2-2021 Shareholder Update Call
(Reference to “year-end” was included incorrectly)NEW HAVEN, Conn., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2021 update call on Monday, August 23rd at 5:00 PM ET. The call...
GlobeNewswire · 08/13 14:48
Precipio Announces Q2-2021 and year-end Shareholder Update Call
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2021 update call on Monday, August 23 at 5:00 PM ET. The call will include updates on all of the company's current core businesses.
GlobeNewswire · 08/12 21:00
Insider Trends: 90-Day Insider Selling Trend Prolonged at Precipio
MT Newswires · 08/03 13:20
BRIEF-Precipio Announces Preliminary Unaudited Q2-2021 Revenues Of $2.3 Mln
reuters.com · 07/28 16:17
Precipio Announces Preliminary Unaudited Q2-2021 Revenues of $2.3M
Specialty diagnostics Company Precipio, Inc. (NASDAQ: PRPO), announces preliminary unaudited revenues for Q2-2021 demonstrating continued substantial YoY and quarterly growth.
GlobeNewswire · 07/28 14:00
Thinking about buying stock in Allied Esports Entertainment, Frontline, Naked Brand, Chevron, or Precipio?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AESE, FRO, NAKD, CVX, and PRPO.
PR Newswire - PRF · 07/02 13:31
Webull provides a variety of real-time PRPO stock news. You can receive the latest news about PRECIPIO through multiple platforms. This information may help you make smarter investment decisions.
About PRPO
Precipio, Inc. is a cancer diagnostics and reagent technology company providing diagnostic products and services to the oncology market. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables culturing of all four hematopoietic cell lineages, which include myeloid cells, B-cells, T-cells and plasma cells. The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture based tests by a cytogenetics laboratory to imitate in-vivo conditions. HemeScreen technology was developed by the Company targeting Myeloproliferative Neoplasms (MPN), which has evolved into a suite of robust genetic diagnostic panels. ICP technology was developed at Harvard and is licensed exclusively by Dana-Farber. The Company operate a cancer diagnostic laboratory located in New Haven.